We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+67.56%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$955M
AUM Growth
+$389M
Cap. Flow
+$199M
Cap. Flow %
20.8%
Top 10 Hldgs %
58.81%
Holding
63
New
12
Increased
9
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$78.8M
2
APLS
Apellis Pharmaceuticals
APLS
+$55.5M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$26.9M
4
BPMC
Blueprint Medicines
BPMC
+$26.4M
5
IFRX icon
InflaRx
IFRX
+$26M

Top Sells

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$43.2M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$27M
3
OMER icon
Omeros
OMER
+$15.5M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$11.9M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 83.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
26
DELISTED
Audentes Therapeutics, Inc
BOLD
$10.6M 1.11%
337,876
+14,331
+4% +$393K
ABEO icon
27
Abeona Therapeutics
ABEO
$369M
$9.11M 0.95%
23,000
+7,000
+44% +$2.89M
ARRY
28
DELISTED
Array Biopharma Inc
ARRY
$8.96M 0.94%
700,000
-200,000
-22% -$2.27M
PTGX icon
29
Protagonist Therapeutics
PTGX
$8.92B
$8.32M 0.87%
400,000
-100,000
-20% -$1.77M
BHVN
30
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.04M 0.84%
+297,803
New +$8.2M
WVE icon
31
Wave Life Sciences
WVE
$1.11B
$7.09M 0.74%
202,079
– –
ZLAB icon
32
Zai Lab
ZLAB
$2.06B
$7.07M 0.74%
333,166
– –
SGMO
33
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.56M 0.69%
400,000
– –
MTVA
34
MetaVia Inc
MTVA
$7.44M
$6.36M 0.67%
12
– –
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.66M 0.59%
200,000
-188,574
-49% -$5.26M
COLL icon
36
Collegium Pharmaceutical
COLL
$1.17B
$5.54M 0.58%
300,000
– –
MRSN
37
DELISTED
Mersana Therapeutics
MRSN
$4.86M 0.51%
11,822
– –
JNCE
38
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$4.68M 0.49%
367,223
+7,485
+2% +$110K
TRIL
39
DELISTED
Trillium Therapeutics Inc.
TRIL
$4.38M 0.46%
600,000
– –
INDP icon
40
Indaptus Therapeutics
INDP
$192M
$4.17M 0.44%
362
– –
MRNS
41
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.08M 0.43%
+125,000
New +$3.37M
ARDX icon
42
Ardelyx
ARDX
$1.25B
$3.78M 0.4%
572,738
– –
NERV icon
43
Minerva Neurosciences
NERV
$187M
$3.68M 0.39%
75,988
– –
HRTX icon
44
Heron Therapeutics
HRTX
$94.1M
$3.62M 0.38%
200,000
-370,000
-65% -$6.03M
CFRX
45
DELISTED
ContraFect Corporation
CFRX
$3.59M 0.38%
4,438
– –
XLRN
46
DELISTED
Acceleron Pharma
XLRN
$3.18M 0.33%
75,000
– –
SYRS
47
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.88M 0.3%
29,630
– –
OVID icon
48
Ovid Therapeutics
OVID
$442M
$2.21M 0.23%
223,972
– –
OTLK icon
49
Outlook Therapeutics
OTLK
$194M
$40K ﹤0.01%
191
-3,521
-95% -$730K
ONSIW
50
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$13K ﹤0.01%
416,666
– –
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Cormorant Asset Management held 63 positions worth $955M, up 69% from $566M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management deployed $199M of net new capital in Q4 2017, opening 12 new positions and adding to 9 existing holdings. Its largest new stake was Nektar Therapeutics: 133,180 shares worth $119M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 87% a quarter earlier.

On the sell side, the largest reduction was Omeros, an estimated $15.5M trimmed.

  • Cormorant Asset Management's largest Q4 2017 buy was Nektar Therapeutics: 133,180 shares worth $119M.
  • Cormorant Asset Management added most to Blueprint Medicines in Q4 2017, an estimated $26.4M increase.
  • Cormorant Asset Management's biggest Q4 2017 reduction was Omeros, cutting an estimated $15.5M.
  • Cormorant Asset Management fully exited Ignyta, Inc. in Q4 2017, selling an estimated $43.2M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $955M portfolio in Q4 2017.
  • Cormorant Asset Management opened 12 new positions and closed 11 in Q4 2017.
  • Cormorant Asset Management's portfolio value rose 69% quarter-over-quarter to $955M.

Based on Cormorant Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.